{
    "clinical_study": {
        "@rank": "83815", 
        "arm_group": {
            "arm_group_label": "Cabazitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m\u00b2 by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether cabazitaxel is effective in the treatment\n      of metastatic breast cancer."
        }, 
        "brief_title": "Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Female patients aged 18 to 75 years\n\n          -  Patients must have received 1st-line chemotherapy for locally recurrent / metastatic\n             disease\n\n          -  Prior taxane-containing treatment (paclitaxel, docetaxel or nab-paclitaxel), either\n             for advanced disease or as neoadjuvant/adjuvant chemotherapy. In case of early\n             relapse (relapse during neoadjuvant/adjuvant chemotherapy or disease-free interval\n             less than 6 months), neoadjuvant/adjuvant chemotherapy will be considered as 1st-line\n             treatment\n\n          -  Diagnosis of HER-2 negative (HER-2 <2+ by immunohistochemistry and/or FISH or CISH\n             negative) metastatic breast adenocarcinoma confirmed by the pathology department of\n             the enrolling institution\n\n          -  Eastern Cooperative Oncology Group performance status (PS) of 0-1\n\n          -  Life expectancy of at least 12 weeks\n\n          -  Measurable disease by the Response Criteria in Solid Tumors 1.1 (RECIST 1.1) method\n             (at least one measurable lesion)\n\n          -  Laboratory values within the specified ranges within 1 week of study enrolment:\n\n               1. Hemoglobin \u2265 9.0 g/dL\n\n               2. Absolute neutrophil count of \u2265 1.5 x 10^9/L\n\n               3. Thrombocyte count of \u2265 100 x 10^9/L\n\n               4. Serum creatinine \u2264 1.5 upper limit of normal (ULN). If creatinine 1.0 - 1.5 x\n                  ULN, creatinine clearance will be calculated according to CKD-EPI formula and\n                  patients with creatinine clearance <60 mL/min should be excluded\n\n               5. SGOT (AST), SGPT (ALT) \u2264 2.5 x ULN and alkaline phosphatase \u2264 2.5 x ULN, total\n                  bilirubin \u2264 ULN (the same limits also refer to patients with liver metastases)\n\n          -  Previous treatment for loco-regional disease is allowed, including surgical\n             procedures or palliative radiotherapy (such treatments must have been completed at\n             least 4 weeks before enrolment)\n\n          -  Compliance of the patient regarding scheduled visits, treatment plan, laboratory\n             tests and other procedures of the study.\n\n          -  The enrolment of patients with controlled brain metastases is allowed (metastases\n             that have been treated with radiotherapy and remained stable for at least 4 weeks\n             following the completion of radiation treatment)\n\n        Exclusion Criteria:\n\n          -  Patients that have received more than one lines of chemotherapy for locally\n             recurrent/metastatic disease\n\n          -  Concurrent or planned treatment with strong inhibitors or strong inducers of\n             cytochrome P450 3A4/5 (a wash-out period of two weeks is necessary for patients who\n             are already on these treatments)\n\n          -  Patients with CTC grade 2 or greater neuropathy at baseline\n\n          -  Diagnosis of spinal cord compression or carcinomatous meningitis\n\n          -  Uncontrolled severe illness or medical condition (including uncontrolled diabetes\n             mellitus)\n\n          -  Patients with clinically significant cardiac disease (e.g. congestive heart failure,\n             unstable angina, myocardial infarction) within 6 months from study entry\n\n          -  Any other significant acute or chronic medical or psychiatric condition or abnormal\n             laboratory finding which, according to the investigator's opinion, could result in\n             excessive danger, regarding the participation of the patient in the study.\n\n          -  Psychiatric disorders or other conditions rendering the subject incapable of\n             complying with the requirements of the protocol\n\n          -  Any concurrent active malignancy other than non-melanoma skin cancer or in situ\n             carcinoma of the cervix\n\n          -  Concurrent administration of other investigational treatments and/or anti-neoplastic\n             agents\n\n          -  Pregnancy or lactation. Patients should be surgically sterile or post-menopausal or\n             they must agree to use adequate contraceptive methods during study period. For all\n             patients of childbearing potential a serum or urine pregnancy test is needed. The\n             definition of effective contraceptive methods will be based on the investigator's\n             opinion.\n\n          -  History of severe hypersensitivity reaction (\u2265grade 3) to docetaxel or polysorbate 80\n             containing drugs"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693549", 
            "org_study_id": "HE 11B/11", 
            "secondary_id": "2011-003625-97"
        }, 
        "intervention": {
            "arm_group_label": "Cabazitaxel", 
            "intervention_name": "Cabazitaxel", 
            "intervention_type": "Drug", 
            "other_name": [
                "Jevtana", 
                "XRP6258"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HER-2 negative", 
            "Metastatic breast adenocarcinoma"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "psyrri237@yahoo.gr", 
                    "last_name": "Diamanto Psyrri, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "12462"
                    }, 
                    "name": "Division of Oncology, 2nd Dept of Internal Medicine, Propaedeutic, University Hospital \"Attikon\""
                }, 
                "investigator": {
                    "last_name": "Diamanto Psyrri, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chr_papadim@yahoo.gr", 
                    "last_name": "Christos Papadimitriou, Ass.Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11528"
                    }, 
                    "name": "Oncology section, Dept of Clinical Therapeutics, General Hospital of Athens \"Alexandra\""
                }, 
                "investigator": {
                    "last_name": "Christos Papadimitriou, Ass.Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dimmp@otenet.gr", 
                    "last_name": "Dimitrios Bafaloukos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "18547"
                    }, 
                    "name": "1st Dept of Medical Oncology, Metropolitan Hospital"
                }, 
                "investigator": {
                    "last_name": "Dimitrios Bafaloukos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hecogiat@otenet.gr", 
                    "last_name": "Dimosthenis V. Skarlos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "18547"
                    }, 
                    "name": "2nd Dept of Medical Oncology, Metropolitan Hospital"
                }, 
                "investigator": {
                    "last_name": "Dimosthenis V. Skarlos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "smart12@otenet.gr", 
                    "last_name": "Christos Panopoulos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "2nd Dept of Medical Oncology, Agios Savvas Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Christos Panopoulos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hecogaga@otenet.gr", 
                    "last_name": "Eleni Res, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "14564"
                    }, 
                    "name": "3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital"
                }, 
                "investigator": {
                    "last_name": "Eleni Res, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pectasid@otenet.gr", 
                    "last_name": "Dimitrios Pectasides, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }, 
                    "name": "2nd Dept of Medical Oncology, General Hospital of Athens \"Hippokratio\""
                }, 
                "investigator": {
                    "last_name": "Dimitrios Pectasides, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "e.razis@hygeia.gr", 
                    "last_name": "Evangelia Razis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "15123"
                    }, 
                    "name": "3rd Dept of Medical Oncology, Hygeia Hospital"
                }, 
                "investigator": {
                    "last_name": "Evangelia Razis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oncol@chaniahospital.gr", 
                    "last_name": "Ioannis Varthalitis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Chania", 
                        "country": "Greece", 
                        "zip": "73300"
                    }, 
                    "name": "Oncology Dept., General Hospital of Chania \"Agios Georgios\""
                }, 
                "investigator": {
                    "last_name": "Ioannis Varthalitis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "georgoul@med.uoc.gr", 
                    "last_name": "Vassilios Georgoulias, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Heraklio", 
                        "country": "Greece", 
                        "zip": "71110"
                    }, 
                    "name": "Dept of Medical Oncology, University Hospital of Heraklion"
                }, 
                "investigator": {
                    "last_name": "Vassilios Georgoulias, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gpenther@otenet.gr", 
                    "last_name": "George Pentheroudakis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ioannina", 
                        "country": "Greece", 
                        "zip": "45110"
                    }, 
                    "name": "Dept of Medical Oncology, Ioannina University Hospital"
                }, 
                "investigator": {
                    "last_name": "George Pentheroudakis, Ass.Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cpapandreou@med.uth.gr", 
                    "last_name": "Christos Papandreou, Ass.Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Larissa", 
                        "country": "Greece", 
                        "zip": "41334"
                    }, 
                    "name": "Dept of Medical Oncology, Larissa University Hospital"
                }, 
                "investigator": {
                    "last_name": "Christos Papandreou, Ass.Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "angkoutr@otenet.gr", 
                    "last_name": "Angelos Koutras"
                }, 
                "facility": {
                    "address": {
                        "city": "Rio, Patras", 
                        "country": "Greece", 
                        "zip": "26504"
                    }, 
                    "name": "Division of Oncology, Dept of Internal Medicine, University Hospital of Patras"
                }, 
                "investigator": {
                    "last_name": "Angelos Koutras, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gfountzil@auth.gr", 
                    "last_name": "George Fountzilas, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece", 
                        "zip": "56429"
                    }, 
                    "name": "Dept of Medical Oncology, Papageorgiou General Hospital"
                }, 
                "investigator": {
                    "last_name": "George Fountzilas, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes", 
        "overall_contact": {
            "email": "angkoutr@otenet.gr", 
            "last_name": "Angelos Koutras, MD", 
            "phone": "0030 261 0 999810"
        }, 
        "overall_official": {
            "affiliation": "Division of Oncology,Dept of Internal Medicine,University Hospital of Patras", 
            "last_name": "Angelos Koutras, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Greece: National Organization of Medicines", 
                "Greece: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective response rate (ORR).", 
            "safety_issue": "No", 
            "time_frame": "At an average of 24 months for each patient"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693549"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of response.", 
                "safety_issue": "No", 
                "time_frame": "From the time measurement criteria are first met for partial or complete response until the first date of documented progressive disease or death from any cause without prior documentation of progression assessed up to 30 months."
            }, 
            {
                "measure": "Evaluation of progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From study entry until the first date of documented progressive disease (PD) or death from any cause without prior documentation of progression, assessed up to 30 months."
            }, 
            {
                "measure": "Evaluation of overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Defined as the time in months from study entry until the time of death, assessed up to 30 months."
            }, 
            {
                "description": "Distribution of adverse events according to severity grade.", 
                "measure": "Assessment of safety and tolerability.", 
                "safety_issue": "Yes", 
                "time_frame": "Evaluation of Adverse Events will be performed every 21 days (per cycle) during treatment assessed up to 30 months."
            }, 
            {
                "description": "\u03b2\u0399,\u03b2\u0399\u0399,\u03b2\u0399\u0399\u0399,\u03b2IVb, \u03b2V-tubulin isotypes,HIF1\u03b1,microtubule-associated proteins such as Tau,MAP2,MAP4 & microtubule-sequestering proteins such as stathmin, will be assessed. Moreover, evaluation of p53,BCL2,BIM,\u03b3-actin,LIMK2, TGFBI,Aurora-A,as well as the expression of the enzyme CYP3A and multidrug transporters such as P-glycoprotein. The abovementioned factors will be assessed by immunohistochemistry at the protein level and by quantitative real-time PCR at the RNA level.\nAlso, given the clinical significance of the anti-angiogenic effects of cytotoxic chemotherapy,we will investigate the effect of treatment on surrogate biomarkers of angiogenesis, such as VEGF-A as well as the effect of chemotherapy on kinetics of soluble biomarkers,using ELISA.\nIn addition,genetic polymorphisms in drug-metabolizing enzymes and drug transporters, such as the CYP3A and ABCB1 genes, will be explored in blood DNA and their association with the toxicity and efficacy of cabazitaxel will be assessed.", 
                "measure": "Value of prognostic and/or predictive biomarkers measured in tissue and blood samples", 
                "safety_issue": "No", 
                "time_frame": "Tumor blocks and blood DNA will be collected at study entry and plasma at study entry, on week 3 and week 6 of treatment."
            }
        ], 
        "source": "Hellenic Cooperative Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Hellenic Cooperative Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}